Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2011 Scrip 100: Cardiovascular trials

This article was originally published in Scrip

Executive Summary

In the cardiovascular therapeutic area, 133 industry-sponsored Phase II to Phase III trials were initiated between 1 October 2009 and 30 September 2010. Trials were distributed slightly in favour of Phase II over Phase III (66 and 62 studies, respectively), with an additional five Phase II/III trials. Hypertension dominated new trial activity, accounting for more than 25% of new studies overall and more than double the number of trial starts in any other disease. Trials for hypertension were evenly distributed between Phase II and Phase III, with studies for essential hypertension outnumbering trials for pulmonary hypertension by a 3:2 margin. Novartis initiated the most hypertension trials with six, followed by the AstraZeneca/Bristol-Myers Squibb collaboration and Actelion with four, and Bayer and United Therapeutics with three. Hypertension trials sponsored by the latter three companies were concentrated in pulmonary hypertension. Novartis and Pfizer were the only companies to initiate trials in both essential and pulmonary hypertension.

You may also be interested in...


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts